ENSYSCE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 106.82% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2025-03-10
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-03-31 was 95.87%.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 106.82%, a 11.42% increase from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 95.87%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2023-12-31 | 106.82% 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 95.87% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 95.87% 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | 95.87% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 95.87% 10-K · filed 2024-03-15 | |||
| 2022-09-30 | 95.87% 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |